Telomir Pharmaceuticals, Inc. (TELO)
The price, the headline numbers and the latest news, in one place.
Telomir Pharmaceuticals, Inc. (TELO) Stock Price, Analysis & Data
No data available
| Bid | 0.84 |
| Market Cap | 80.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52M |
| -0.25 | |
| -1.11 | |
| n/a | |
| -4.2 | |
| P/B (ttm) | 8.16 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 1.51 |
| Volume | 33,918 |
| Avg. Volume (20D) | 95,719 |
| Open | 1.17 |
| Previous Close | 1.17 |
| Day's Range | 1.16 - 1.18 |
| 52-Week Range | 0.89 - 2.09 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TELO
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic re...
Financial Performance
In 2025, Telomir Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.41M, a decrease of -37.01%.
Financial StatementsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.03 exceeds estimates by 0.04, with -Infinity% YoY decline.
1 year ago · Associated Press Finance
BC-Most Active Stockstd class="col-issue">Next Technology Holding Inc.